{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:37:50Z","timestamp":1791729470492,"version":"4.3.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2003,2,4]],"date-time":"2003-02-04T00:00:00Z","timestamp":1044316800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2003,4]]},"DOI":"10.1007\/s00520-002-0435-3","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T03:52:49Z","timestamp":1576122769000},"page":"249-257","source":"Crossref","is-referenced-by-count":56,"title":["Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients"],"prefix":"10.1007","volume":"11","author":[{"given":"L.","family":"Annemans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Moeremans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lamotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Garcia Conde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Myint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Uyttebroeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,2,4]]},"reference":[{"key":"0435_CR1","doi-asserted-by":"crossref","first-page":"PCN8","DOI":"10.1046\/j.1524-4733.2001.004001008.x","volume":"4","author":"Annemans","year":"2001","unstructured":"Annemans L, Moeremans K (2001) Cost of managing severe hyperuricemia and tumour lysis syndrome in haematologic malignancies (abstract). Value Health 4(6):PCN8","journal-title":"Value Health"},{"key":"0435_CR2","first-page":"the","volume":"al","author":"Berrino","year":"1999","unstructured":"Berrino F, Capocaccia R, Est\u00e8ve J, Gatta G, Hakulinen T, Micheli A, et al (1999) Survival of cancer patients in Europe: the EUROCARE-2 study (scientific publication no. 151). International Agency for Research on Cancer, Lyon","journal-title":"et"},{"key":"0435_CR3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0959-8049(01)00013-2","volume":"37","author":"Coebergh","year":"2001","unstructured":"Coebergh JW, Pastore G, Gatta G, Corazziori I, Kamps W, and The Eurocare Working Group (2001) Variation in survival of European children with acute lymphoblastic leukaemia diagnosed in 1978\u20131992: the EUROCARE study. Eur J Cancer 37:687\u2013694","journal-title":"Eur J Cancer"},{"key":"0435_CR4","unstructured":"Coleman MP, Babb P, Damiecki P, Grosclaude P, Honjo S, Jones J, et al (2001) Cancer survival trends in England and Wales, 1971\u20131995: deprivation and NHS region (Studies in Medical and Population Subjects no. 61). Office for National Statistics, London"},{"key":"0435_CR5","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jama.1996.03540170053032","volume":"276","author":"Diabetes","year":"1996","unstructured":"Diabetes Control and Complications Trial Research Group (1996) Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA 276:1409\u20131415","journal-title":"JAMA"},{"key":"0435_CR6","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0959-8049(01)00045-4","volume":"37","author":"Gatta","year":"2001","unstructured":"Gatta G, Luksch R, Coleman M.P, Corazziari I, and The Eurocare Working Group (2001) Survival from acute non-lymphocytic leukaemia (ANLL) and chronic myeloid leukaemia (CML) in European children since 1978: a population-based study. Eur J Cancer 37:695\u2013702","journal-title":"Eur J Cancer"},{"key":"0435_CR7","doi-asserted-by":"crossref","unstructured":"Gold MR, Siegel JE, Russel LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York Oxford","DOI":"10.1093\/oso\/9780195108248.001.0001"},{"key":"0435_CR8","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1182\/blood.V97.10.2998","volume":"97","author":"Goldman","year":"2001","unstructured":"Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, et al (2001) A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk of tumor lysis. Blood 97:2998\u20133003","journal-title":"Blood"},{"key":"0435_CR9","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","volume":"92","author":"Grimwade","year":"1998","unstructured":"Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92:2322\u20132333","journal-title":"Blood"},{"key":"0435_CR10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF00860751","volume":"9","author":"Jones","year":"1995","unstructured":"Jones DP, Mahmoud H, Chesney RW (1995) Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol 9:206\u2013212","journal-title":"Pediatr Nephrol"},{"key":"0435_CR11","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0959-8049(01)00002-8","volume":"37","author":"Pastore","year":"2001","unstructured":"Pastore G, Magnani C, Verdecchia A, Pession A, Viscomi S, Coebergh JWW, et al (2001) Survival of childhood lymphomas in Europe, 1978\u20131992: a report from the EUROCARE study. Eur J Cancer 37:703\u2013710","journal-title":"Eur J Cancer"},{"key":"0435_CR12","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/sj.leu.2400850","volume":"11","author":"Pui","year":"1997","unstructured":"Pui CH, Relling MV, Lascombes F, Harrison PL, Struxiano A, Mondesir JM, et al (1997) Urate oxidase in prevention and treatment of hyperuricaemia associated with lymphoid malignancies. Leukemia 11:1813\u20131816","journal-title":"Leukemia"},{"key":"0435_CR13","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/sj.leu.2402235","volume":"15","author":"Pui","year":"2001","unstructured":"Pui CH, Jeha S, Irwin D, Camitta B (2001) Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy associated hyperuricemia in paediatric and adult patients: results of a compassionate use trial. Leukemia 15:1505\u20131509","journal-title":"Leukemia"},{"key":"0435_CR14","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2001.19.3.697","volume":"19","author":"Pui","year":"2001","unstructured":"Pui CH, Mahmoud H, Wiley JM, Woods GM, Leverger G, Camitta B, et al (2001) Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 19:697\u2013704","journal-title":"J Clin Oncol"},{"key":"0435_CR15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/hec.4730030507","volume":"3","author":"Rutten-van","year":"1994","unstructured":"Rutten-van Molken MP, van Doorslaer EK, van Vliet RC (1994) Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Econ 3:333\u2013345","journal-title":"Health Econ"},{"key":"0435_CR16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1055\/s-2008-1043892","volume":"210","author":"K Seidemann","year":"1998","unstructured":"Seidemann K, Meyer U, Jansen P, Yakisan E, Rieske K, F\u00fchrer M, et al (1998) Impaired renal function and tumor lysis syndrome in pediatric patients with non-Hodgkin's lymphoma and B-ALL. Observations from the BFM-trials. Klin P\u00e4driatr 210:279\u2013284","journal-title":"Klin P\u00e4driatr"},{"key":"0435_CR17","first-page":"2442","volume":"144","author":"Simoons","year":"2000","unstructured":"Simoons ML (2000) Cholesterol-lowering therapy; a recommendation from the Health Council (in Dutch). Ned Tijdschr Geneeskd 144:2442\u20132444","journal-title":"Ned Tijdschr Geneeskd"},{"key":"0435_CR18","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1136\/bmj.321.7259.510","volume":"321","author":"Stolk","year":"2000","unstructured":"Stolk E, Busschbach J (2000) Cost effectiveness of sildenafil calls for political discussion. BMJ 321:510","journal-title":"BMJ"},{"key":"0435_CR19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1358\/dot.1999.35.2.527964","volume":"35","author":"Tomera","year":"1999","unstructured":"Tomera JF (1999) Acute tumor lysis syndrome: considerations of cause and prevention. Drugs Today 35:79\u201387","journal-title":"Drugs Today"},{"key":"0435_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0300-2977(99)00124-2","volume":"56","author":"Van","year":"2000","unstructured":"Van Der Klooster JM, Van Der Wiel HE, Van Saase JLCM, Grootendorst AF (2000) Asystole during combination chemotherapy for non-Hodgkin's lymphoma: the acute tumor lysis syndrome. Neth J Med 56:147\u2013152","journal-title":"Neth J Med"},{"key":"0435_CR21","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.1016\/S0272-6386(99)70062-4","volume":"34","author":"Wolf","year":"1999","unstructured":"Wolf G, Hegewisch-Becker S, Hossfeld DK, Stahl RAK (1999) Hyperuricaemia and renal insufficiency associated with malignant disease: urate oxidase as an efficient therapy? Am J Kidney Dis 34:E20","journal-title":"Am J Kidney Dis"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-002-0435-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-002-0435-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-002-0435-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T13:01:14Z","timestamp":1722171674000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-002-0435-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["0435"],"URL":"https:\/\/doi.org\/10.1007\/s00520-002-0435-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2,4]]}}}